Provenge: Revolutionary technology or ethical bust? Commentary

Human Vaccines

Volumn 7, Issue 4, 2011, Pages

  Dickerson, Justin B ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Bioethics; Distributive justice; Equity; Prostate cancer; Provenge

Indexed keywords

BEVACIZUMAB; PROVENGE; CANCER VACCINE; SIPULEUCEL-T; TISSUE EXTRACT;

AUTOLOGOUS CELLULAR IMMUNOTHERAPY; BIOETHICS; BREAST CANCER; CANCER IMMUNOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; ETHICAL DECISION MAKING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; HUMAN RIGHTS ABUSE; JUSTICE; NOTE; PROSTATE CANCER; QUALITY OF LIFE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ECONOMICS; ETHICS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; PROSTATE TUMOR; REVIEW;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 79955004752     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.4.14189     Document Type: Note

References (24)

1. Lange P. The PROVENGE story and its importance to urology. AUA news 2010; 15:7.
2. Food and Drug Administration. FDA approves a cellular immunotherapy for men with advanced prostate cancer 2010; Accessed: 11/6/2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm.
3. Dendreon Corporation. Prostate cancer treatment|metastatic castrate resistant (hormone refractory)|provenge.com 2010; Accessed: 11/6/2010. Available at: http://www.provenge.com/about-autologous-cellular-immunotherapy.aspx.
4. Dimond P. What comes after Dendreon's provenge? Accessed: 11/6/2010. Available at: http://www.genengnews.com/analysis-and-insight/what-comes-after- dendreon-s-provenge/77899342/.2010.
5. Kantoff P, Higano C, Shore N, Berger ER, Small E, Penson D, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
6. Hunt T, Luce B, Page M, Pokrzywinski R. Willingness to pay for cancer prevention. Pharmacoeconomics 2009; 27:299-312.
7. Edwards J. Provenge, a new $93K cancer drug, will be extremely effective - on taxpayers|BNET 2010; Accessed: 11/6/2010. Available at: http://www.bnet. com/blog/drug-business/provenge-a-new-93k-cancer-drug-will-be- extremely-effective-8212-on-taxpayers/4721.
8. Krohn D. Dendreon and provenge: What if we lived in england? - seeking alpha 2010; Accessed: 11/6/2010. Available at: http://seekingalpha.com/article/ 213421-dendreon-and-provenge-what-if-we-lived-in-england.
9. Feuerstein A. Dendreon: Medicare coverage fears allayed - TheStreet 2010; Accessed: 11/6/2010. Available at: http://www.thestreet.com/story/10849248/1/ dendreon-medicare-coverage-fears-allayed.html.
10. Yard D. Unique treatment raises tricky bioethical issues. Renal urology news staff 2010; 9:28-30.
11. Winslow R. For Dendreon's provenge, a new competitor looms - health blog - WSJ 2010; Accessed: 11/6/2010. Available at: http://blogs.wsj.com/health/2010/ 10/12/for-dendreons-provenge-a-new-competitor-looms/.
12. Beauchamp T, Childress J. Principles of Biomedical Ethics. New York: Oxford University Press 2001; 5.
13. Lee MJH. The problem of 'thick in status, thin in content' in beauchamp and childress' principlism. J Med Ethics 2010; 36:525-528.
14. Thornton T. Judgement and the role of the metaphysics of values in medical ethics. J Med Ethics 2006; 32:365-70. (Pubitemid 43905292)
15. Lamont J, Favor C. Distributive justice (stanford encyclopedia of philosophy) 2007; Accessed: 11/6/2010. Available at: http://plato.stanford.edu/ entries/justice-distributive/.
16. United States Government Printing Office. US government printing office - FDsys - more information 2010; Accessed: 11/7/2010. Available at: http://www.gpo.gov/fdsys /pkg/PLAW-111publ148/content-detail.htm.
17. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes Oxford [Oxfordshire]; Oxford University Press 1987.
18. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year. Medical Decision Making 2000; 20:332-42. (Pubitemid 30479101)
19. National Cancer Institute. Human papillomavirus (HPV) vaccines 2009; Accessed: 9/3/2010. Available at: http://www.cancer.gov/cancertopics/factsheet/ Prevention/HPV-vaccine.
20. National Conference of State Legislatures. HPV vaccine 2010; Accessed: 9/3/2010. Available at: http://www.ncsl.org/default.aspx?tabid=14381.
21. Associated Press. FDA delays breast cancer drug avastin decision - CBS news 2010; Accessed: 11/7/2010. Available at: http://www.cbsnews.com/stories/ 2010/09/17/health/main6877341.shtml.
22. Kaufman SR. Making longevity in an aging society: Linking ethical sensibility and medicare spending. Med Anthropol 2009; 28:317-25.
23. Callahan D. Life extension: Rolling the technological dice. Society 2009; 46:214-220.
24. Davis J. Life-extension and the malthusian objection. J Med Philos 2005; 30:27-44. (Pubitemid 40546077)